Complete financial analysis of Accuray Incorporated (ARAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Accuray Incorporated, a leading company in the Medical – Specialties industry within the Healthcare sector.
- Solarpack Corporacion Tecnologica, S.A. (SPK.MC) Income Statement Analysis – Financial Results
- New World Brands, Inc. (NWBD) Income Statement Analysis – Financial Results
- Alfabs Australia Limited (AAL.AX) Income Statement Analysis – Financial Results
- Global Digital Creations Holdings Limited (8271.HK) Income Statement Analysis – Financial Results
- Forest Road Acquisition Corp. II (FRXB) Income Statement Analysis – Financial Results
Accuray Incorporated (ARAY)
About Accuray Incorporated
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 446.55M | 447.61M | 429.91M | 396.29M | 382.93M | 418.79M | 404.90M | 383.41M | 398.80M | 379.80M | 369.42M | 315.97M | 409.22M | 222.28M | 221.63M | 233.60M | 210.38M | 140.45M | 52.90M | 22.38M | 19.57M | 2.71M | 19.35M |
| Cost of Revenue | 303.63M | 293.65M | 269.95M | 236.78M | 233.06M | 256.13M | 243.20M | 242.07M | 240.09M | 234.40M | 226.62M | 218.33M | 271.95M | 115.04M | 117.61M | 118.31M | 103.43M | 60.41M | 27.49M | 11.12M | 0.00 | 3.03M | 0.00 |
| Gross Profit | 142.92M | 153.96M | 159.96M | 159.51M | 149.87M | 162.65M | 161.70M | 141.34M | 158.71M | 145.40M | 142.80M | 97.64M | 137.27M | 107.24M | 104.02M | 115.29M | 106.95M | 80.04M | 25.41M | 11.26M | 19.57M | -317.00K | 19.35M |
| Gross Profit Ratio | 32.01% | 34.40% | 37.21% | 40.25% | 39.14% | 38.84% | 39.93% | 36.86% | 39.80% | 38.28% | 38.66% | 30.90% | 33.54% | 48.25% | 46.93% | 49.35% | 50.84% | 56.99% | 48.03% | 50.33% | 100.00% | -11.70% | 100.00% |
| Research & Development | 49.73M | 57.13M | 57.75M | 52.73M | 49.78M | 56.49M | 57.25M | 49.92M | 56.65M | 55.75M | 53.72M | 66.20M | 87.11M | 41.69M | 31.52M | 35.99M | 32.88M | 26.78M | 17.79M | 11.66M | 0.00 | 5.84M | 0.00 |
| General & Administrative | 50.07M | 48.27M | 44.39M | 41.72M | 40.97M | 49.58M | 48.14M | 43.77M | 50.12M | 46.38M | 45.34M | 57.73M | 58.60M | 56.66M | 35.47M | 36.22M | 32.28M | 23.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 42.62M | 46.18M | 49.66M | 42.82M | 47.25M | 56.00M | 60.11M | 57.48M | 56.81M | 62.44M | 61.89M | 54.37M | 54.55M | 37.18M | 34.19M | 45.49M | 42.73M | 37.89M | 0.00 | 0.00 | 0.00 | 6.71M | 0.00 |
| SG&A | 92.69M | 94.45M | 94.06M | 84.54M | 88.22M | 105.58M | 108.24M | 101.24M | 106.93M | 108.82M | 107.22M | 112.10M | 113.15M | 93.84M | 69.66M | 81.72M | 75.01M | 61.80M | 41.11M | 24.49M | 0.00 | 6.71M | 0.00 |
| Other Expenses | 0.00 | -11.74M | -10.39M | -27.67M | -6.70M | -14.93M | -19.22M | -18.72M | -18.30M | -18.62M | -14.22M | -13.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.02M | -24.75M |
| Operating Expenses | 142.42M | 151.58M | 151.81M | 137.27M | 138.00M | 162.07M | 165.49M | 151.16M | 163.59M | 164.57M | 160.94M | 178.30M | 200.26M | 135.53M | 101.18M | 117.71M | 107.89M | 88.58M | 58.90M | 36.15M | 0.00 | 15.57M | -24.75M |
| Cost & Expenses | 446.05M | 445.22M | 421.76M | 374.05M | 371.06M | 418.20M | 408.69M | 393.24M | 403.67M | 398.97M | 387.56M | 396.63M | 472.21M | 250.57M | 218.79M | 236.02M | 211.32M | 148.99M | 86.39M | 47.26M | 0.00 | 18.60M | -24.75M |
| Interest Income | 0.00 | 10.63M | 8.13M | 16.89M | 18.08M | 15.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 360.00K | 543.00K | 1.00K | 3.08M | 7.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 11.62M | 10.63M | 8.13M | 16.89M | 18.08M | 15.08M | 14.96M | 17.30M | 17.46M | 16.52M | 14.29M | 10.38M | 7.81M | 23.00K | 32.00K | 10.00K | 173.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.91M | 4.53M | 5.51M | 6.39M | 7.54M | 10.49M | 9.73M | 18.00M | 18.30M | 19.49M | 20.56M | 25.56M | 32.59M | 7.57M | 7.12M | 6.65M | 7.69M | 6.25M | 3.81M | 2.08M | 0.00 | 0.00 | 24.75M |
| EBITDA | 5.71M | 9.61M | 13.66M | 28.62M | 20.08M | 11.07M | 1.67M | 6.80M | 12.59M | -1.78M | 2.49M | -57.85M | -35.46M | -18.43M | 9.99M | 7.33M | 14.11M | 1.39M | -29.69M | -22.80M | 19.57M | -15.89M | 19.35M |
| EBITDA Ratio | 1.28% | 0.53% | 1.90% | 5.61% | 3.10% | 0.14% | -0.94% | -2.56% | -1.22% | -5.05% | -4.91% | -25.53% | -12.25% | -9.08% | 1.28% | -1.04% | 3.21% | -1.36% | -56.12% | -101.90% | 100.00% | -586.20% | 100.00% |
| Operating Income | 504.00K | 2.38M | 2.64M | 15.85M | 4.33M | -9.91M | -3.80M | -9.82M | -4.87M | -19.17M | -18.14M | -80.66M | -62.99M | -28.28M | 2.84M | -2.42M | -934.00K | -8.54M | -33.49M | -24.88M | 19.57M | -15.89M | -5.40M |
| Operating Income Ratio | 0.11% | 0.53% | 0.61% | 4.00% | 1.13% | -2.37% | -0.94% | -2.56% | -1.22% | -5.05% | -4.91% | -25.53% | -15.39% | -12.72% | 1.28% | -1.04% | -0.44% | -6.08% | -63.32% | -111.20% | 100.00% | -586.20% | -27.89% |
| Total Other Income/Expenses | -12.32M | -9.17M | -10.15M | -26.79M | -6.85M | -14.93M | -19.22M | -18.72M | -18.30M | -18.62M | -14.22M | -13.13M | -12.87M | 2.29M | 1.00K | 3.08M | 7.18M | 3.53M | 56.00K | -238.00K | -19.57M | 46.00K | -399.00K |
| Income Before Tax | -11.82M | -6.79M | -2.00M | -4.56M | 5.02M | -14.34M | -23.02M | -28.54M | -23.17M | -37.79M | -32.36M | -93.79M | -75.86M | -26.00M | 2.84M | 664.00K | 6.25M | -5.01M | -33.44M | -25.12M | 0.00 | -15.84M | -5.80M |
| Income Before Tax Ratio | -2.65% | -1.52% | -0.47% | -1.15% | 1.31% | -3.43% | -5.69% | -7.44% | -5.81% | -9.95% | -8.76% | -29.68% | -18.54% | -11.69% | 1.28% | 0.28% | 2.97% | -3.57% | -63.21% | -112.26% | 0.00% | -584.50% | -29.95% |
| Income Tax Expense | 3.73M | 2.49M | 3.35M | 1.75M | 1.86M | 2.09M | 878.00K | 1.04M | 2.34M | 2.42M | 3.09M | 3.57M | 2.60M | 1.12M | -4.00K | 55.00K | 867.00K | 1.44M | 258.00K | 68.00K | 11.70M | 0.00 | -5.80M |
| Net Income | -15.55M | -9.28M | -5.35M | -6.31M | 3.83M | -16.43M | -23.90M | -29.58M | -25.50M | -40.21M | -35.45M | -103.22M | -72.04M | -26.68M | 2.84M | 609.00K | 5.38M | -5.62M | -33.69M | -25.19M | -11.70M | -15.84M | 0.00 |
| Net Income Ratio | -3.48% | -2.07% | -1.24% | -1.59% | 1.00% | -3.92% | -5.90% | -7.71% | -6.40% | -10.59% | -9.60% | -32.67% | -17.60% | -12.00% | 1.28% | 0.26% | 2.56% | -4.00% | -63.70% | -112.57% | -59.77% | -584.50% | 0.00% |
| EPS | -0.16 | -0.10 | -0.06 | -0.07 | 0.04 | -0.19 | -0.28 | -0.36 | -0.32 | -0.51 | -0.47 | -1.41 | -1.02 | -0.44 | 0.05 | 0.01 | 0.10 | -0.18 | -2.11 | -1.76 | -1.00 | -1.49 | -1.21 |
| EPS Diluted | -0.16 | -0.10 | -0.06 | -0.07 | 0.04 | -0.19 | -0.28 | -0.36 | -0.32 | -0.51 | -0.47 | -1.41 | -1.02 | -0.44 | 0.05 | 0.01 | 0.09 | -0.18 | -2.11 | -1.76 | -1.00 | -1.49 | -1.21 |
| Weighted Avg Shares Out | 98.27M | 94.88M | 92.10M | 92.03M | 89.87M | 87.47M | 84.89M | 82.50M | 80.51M | 78.28M | 75.42M | 73.20M | 70.89M | 60.09M | 57.56M | 55.41M | 54.53M | 30.76M | 16.00M | 14.28M | 11.74M | 10.61M | 10.56M |
| Weighted Avg Shares Out (Dil) | 98.27M | 94.88M | 92.10M | 92.03M | 90.62M | 87.47M | 84.89M | 82.50M | 80.51M | 78.28M | 75.80M | 73.28M | 70.89M | 60.09M | 60.19M | 58.73M | 60.43M | 30.76M | 16.00M | 14.28M | 11.74M | 10.61M | 10.56M |
Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA
Accuray Announces Approval of the Accuray Precision® Treatment Planning System by China's National Medical Products Administration
Accuray (ARAY) Up 2% Since Last Earnings Report: Can It Continue?
New Strong Sell Stocks for May 31st
New Strong Sell Stocks for May 24th
Accuray to Participate in the Jefferies Global Healthcare Conference 2024
Accuray (ARAY) Q3 Earnings Lag Estimates, Gross Margin Contracts
Accuray Incorporated (ARAY) Q3 2024 Earnings Call Transcript
Accuray (ARAY) Reports Q3 Loss, Lags Revenue Estimates
Accuray Reports Fiscal 2024 Third Quarter Financial Results
Source: https://incomestatements.info
Category: Stock Reports